The global biodefense market was valued at $13.7 billion in 2021 and it is expected to reach $33.5 billion at a CAGR of 8.0% between 2022 and 2032. To protect a nation's biosecurity from biological poisons or infectious agents that could be used in biological warfare or to kill or infect people, animals, or the environment, biodefense is a collection of medical or military procedures that are implemented. The market for biodefense is being driven by rising private investment, increased government focus on and funding for biodefense techniques and an increase in the occurrence of diverse agents such as the Ebola virus, Zika virus, and flu.
Measures to reestablish biosecurity for a collection of organisms that are, or maybe, vulnerable to biological threats or infectious illnesses are referred to as biodefense. Biodefense is typically thought of as a military or emergency response phrase and is commonly mentioned in the context of bio war or bioterrorism. Moreover, the act of preventing, responding to, and thwarting bioterrorism is referred to as biodefense. In a bioterrorism attack, bacteria, viruses, and other infections that can harm humans, animals, farmland, and the environment are intentionally released. Biodefense refers to a range of medical actions taken to protect people from biological hazards, such as giving vaccines and medications, conducting research, and carrying out different public health operations. Products for biodefense are frequently successful against radiation/nuclear disasters, anthrax, smallpox, botulism, and other similar catastrophes. Biodefense uses medical safeguards to defend individuals from bioterrorism. This covers prescription drugs and immunizations. Medical research and defenses against bioterrorist threats are also included. These primary factors are expected to drive the growth of the market during the forecast period.
Source: SAI Research
Furthermore, one of the main factors propelling the market's expansion is the escalating threat of terrorism, which is linked with the constant rise in international tension. Additionally, the rising defense spending by the governments of various countries to enhance both internal and foreign security is bolstering the market's expansion. One of the main factors propelling the market's expansion is the escalating threat of terrorism, which is linked with the constant rise in international tension. Additionally, the rising defense spending by the governments of various countries to enhance both internal and foreign security is bolstering the market's expansion. However, the rising incidence of zoonotic diseases like Ebola, which is driving up government organizations’ biodefense attempts, is anticipated to support the expansion of the worldwide biodefense market. Throughout the forecast period, rising clinical studies for the Zika vaccine are also anticipated to support the expansion of the global biodefense market.
The development of gene chips for pathogen detection in the forensic division, database management systems, nanotechnology, and advanced detector hardware in the development of bio-defense drugs are just a few of the initiatives that governments are taking to improve readiness against chemical, biological, nuclear, and radiological threats, as well as other technological advancements. These are the main aspects favoring the market for biodefense. The military and governments of every nation are the main buyers of biodefense products. Various pharmaceutical businesses involved in the bio-defense sector have significant chances to grow and be ready for any bioterrorism as governments actively monitor existing and future policies and efforts to comprehend the dangers of bio-security and bio-defense. On the other hand, the financing supplied by authorities in developing and underdeveloped countries for the production of vaccines against bioterrorism attacks is appreciably low and restrains the expansion of the bio-defense market. However, it is also anticipated that during the anticipated years, a lack of government financing for R&D in developing and undeveloped nations may limit market growth for biodefense. Moreover, the development of the market's revenue could be limited to some extent by developing and undeveloped nations' insufficient funding capacity to create effective biodefense systems. The creation of biodefense measures necessitates access to cutting-edge technology, well-stocked facilities, and subject-matter experts.
Based on product type, the anthrax segment holds the largest share of the market and is also anticipated to dominate the market during the forecast period. One of the most plausible tools of bioterrorism is the gram-positive bacteria Bacillus anthrax, which causes anthrax. These spores are mostly favored since they may be put in food, water, powder, and sprays and easily distributed into the environment. They can last for a long time in the environment and are easily found in nature. The market is anticipated to maintain its dominance during the forecast period as a result of increased funding from foreign governments, primarily through the Bio Shield Act, the Biomedical Advanced Research and Development Authority (BARDA), and the Joint Program Executive Office for Chemical & Biological Defense, for the development and stockpiling of adequate anthrax vaccines.
In terms of end-user, the market is segmented into government institutions, hospitals and clinics, ambulatory care centers, and others. The government institution segment is anticipated to propel the market growth during the forecast period. The pharmaceutical firms engaged in the biodefense industry have significant chances to expand and be ready for any bioterrorism as the government engages in these present and future policy initiatives, comprehending the existing biosecurity and biodefense policy. To be ready for any bioterrorism strikes, the government invests extensively in the research and development of vaccinations each year. On the other hand, the hospitals and clinics category would also dominate the market in the future. This segment's expansion can be linked to the availability of historical patient data and the presence of sizable R&D facilities. Due to the presence of highly qualified medical professionals, public health specialists, and laboratories, hospitals can offer a comprehensive approach to dealing with disease outbreaks to save as many lives as possible. Hospitals and medical schools are eager to create new technology so they can respond immediately to any unforeseen events in the future. The creation of new vaccinations, treatments, and diagnostics is combined with fundamental and genomic research at numerous military hospitals and research facilities financed by governments for biodefense. Growth in segment revenue is therefore anticipated to be driven by the expansion of research infrastructure.
Geographically, North America holds the major share of the market and is expected to hold its dominant position over the forecast period. Major corporations' presence in the area is also anticipated to be crucial for market growth. Additionally, plans for creating a biodefense system and emergency responses in the event of biological outbreaks are anticipated to fuel market revenue growth. The planned investments would finance important developments and upgrades to recognize, stop, and offer a protective reaction to potential biological calamities. However, the Asia-Pacific market is expected to become the second-largest market in the future due to rising investments associated with R&D activities. Governments in the region encourage businesses by providing appropriate funding and facilitating the issuance of licenses for the construction of factories and manufacturing facilities for the production of vaccines and pharmaceuticals, which also fosters market expansion in the Asia Pacific region.
According to the study, key players such as Altimune (U.S), Amgen (U.S), Alnylam Pharmaceuticals (U.S), Bavarian Nordic (Denmark), Cleveland Biolabs (U.S), DXC Technology (U.S), Emergent Biosoultions (U.S), Elusys Therapeutics (U.S), Ichor Holdings (U.S), Ology Bio services (U.S), Siga Technologies (U.S), XOMA Corporation (U.S), among others are leading the global biodefense market.
|Market Size in 2021||US$ 13.7 Billion|
|Market Volume Projection by 2032||US$ 33.5 Billion|
|Forecast Period 2022 to 2032 CAGR||8.0%|
|Historical Data||2019, 2020 and 2021|
|Forecast Period||2022 to 2032|
By Product Type: Anthrax, Botulism, Radiation, Small Pox & Others
By End-User Type: Government Institutions, Hospitals and Clinics, Ambulatory Care Centers & Others
North America, Europe, Asia-Pacific, LAMEA
|Companies covered||Altimune (U.S), Amgen (U.S), Alnylam Pharmaceuticals (U.S), Bavarian Nordic (Denmark), Cleveland Biolabs (U.S), DXC Technology (U.S), Emergent Biosoultions (U.S), Elusys Therapeutics (U.S), Ichor Holdings (U.S), Ology Bio services (U.S), Siga Technologies (U.S), XOMA Corporation (U.S) & Others|
The Global Biodefense Market – by Product Type:
The Global Biodefense Market – by End-User Type:
The Global Biodefense Market – by Regions:
Customization options available to meet your custom research requirements :